GSK to sell remaining 4.2% stake in Haleon
GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.
FTSE 100
8,275.38
16:50 31/05/24
n/a
n/a
FTSE 350
4,562.25
17:14 31/05/24
n/a
n/a
FTSE All-Share
4,517.08
16:54 31/05/24
n/a
n/a
GSK
1,766.50p
16:44 31/05/24
2.11%
36.50p
Haleon
325.10p
16:47 31/05/24
0.12%
0.40p
Pharmaceuticals & Biotechnology
23,365.59
17:14 31/05/24
1.42%
327.82
The pharmaceutical company will sell about 385m ordinary shares in consumer health business Haleon, which it spun off in July 2022.
GSK initially retained a 12.9% stake in Haleon, but has since sold stakes in May 2023, October 2023 and January 2024.
The final disposal will be conducted through a placing of ordinary shares to institutional investors. GSK said the offer price will be determined by means of an accelerated bookbuild offering process which will start immediately.